Novo Nordisk (NYSE:NVO) presented new CagriSema clinical data at EASD 2026, including studies evaluating food-related brain responses, organ fat changes and weight reduction in adults with overweight or obesity.
Novo Nordisk (NYSE:NVO) launched a corporate rebrand that will see the company use the shorter “Novo” name in day-to-day communications while retaining Novo Nordisk A/S as its legal name.
Novo Nordisk (NYSE:NVO) and Anthropic announced a collaboration to apply Anthropic’s Claude AI models, including Claude Science, across Novo Nordisk’s research and development and software engineering activities.
Novo Nordisk (NYSE:NVO) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending once-weekly Sogroya (somapacitan) for children in Europe with idiopathic short stature and persistent growth disturbance.
Novo Nordisk (NYSE:NVO) agreed to license Hengrui Pharma’s phase 1-ready oral candidate HRS-1596 in a transaction valued at up to $2.6 billion.
